JP6113850B2 - がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法 - Google Patents

がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法 Download PDF

Info

Publication number
JP6113850B2
JP6113850B2 JP2015536905A JP2015536905A JP6113850B2 JP 6113850 B2 JP6113850 B2 JP 6113850B2 JP 2015536905 A JP2015536905 A JP 2015536905A JP 2015536905 A JP2015536905 A JP 2015536905A JP 6113850 B2 JP6113850 B2 JP 6113850B2
Authority
JP
Japan
Prior art keywords
tumor
hemoglobin
cells
cancer
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015536905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534946A5 (enExample
JP2015534946A (ja
Inventor
ロウ ウォン ビン
ロウ ウォン ビン
ファン マン ワイ ノーマン
ファン マン ワイ ノーマン
イー クォック スイ
イー クォック スイ
ハン ラウ シエ
ハン ラウ シエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vision Global Holdings Ltd
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of JP2015534946A publication Critical patent/JP2015534946A/ja
Publication of JP2015534946A5 publication Critical patent/JP2015534946A5/ja
Application granted granted Critical
Publication of JP6113850B2 publication Critical patent/JP6113850B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015536905A 2012-10-12 2013-10-11 がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法 Expired - Fee Related JP6113850B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261712853P 2012-10-12 2012-10-12
US61/712,853 2012-10-12
US13/713,031 2012-12-13
US13/713,031 US20140106004A1 (en) 2012-10-12 2012-12-13 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
PCT/US2013/064418 WO2014059199A1 (en) 2012-10-12 2013-10-11 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence

Publications (3)

Publication Number Publication Date
JP2015534946A JP2015534946A (ja) 2015-12-07
JP2015534946A5 JP2015534946A5 (enExample) 2016-12-01
JP6113850B2 true JP6113850B2 (ja) 2017-04-12

Family

ID=50475529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015536905A Expired - Fee Related JP6113850B2 (ja) 2012-10-12 2013-10-11 がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法

Country Status (21)

Country Link
US (2) US20140106004A1 (enExample)
EP (1) EP2906222A4 (enExample)
JP (1) JP6113850B2 (enExample)
KR (1) KR20150065881A (enExample)
CN (1) CN104717966B (enExample)
AP (1) AP2015008315A0 (enExample)
AR (1) AR093023A1 (enExample)
AU (1) AU2013329121B2 (enExample)
BR (1) BR112015007475A2 (enExample)
CA (1) CA2884521C (enExample)
CL (1) CL2015000897A1 (enExample)
EA (1) EA201500301A1 (enExample)
IL (1) IL237763A (enExample)
MA (1) MA37994A2 (enExample)
MX (1) MX367562B (enExample)
PH (1) PH12015500562B1 (enExample)
SG (3) SG10201608747RA (enExample)
TW (1) TW201414489A (enExample)
UY (1) UY35082A (enExample)
WO (1) WO2014059199A1 (enExample)
ZA (1) ZA201501949B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911414C (en) * 2013-05-13 2018-09-11 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
CA2952121A1 (en) 2014-06-13 2015-12-17 Childrens' Medical Center Corporation Products and methods to isolate mitochondria
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US20170151287A1 (en) 2015-11-30 2017-06-01 Flagship Ventures Management, Inc. Methods and compositions of chondrisomes
ES3057779T3 (en) * 2016-01-15 2026-03-04 Childrens Medical Ct Corp Therapeutic use of mitochondria and combined mitochondrial agents
CA3028589A1 (en) * 2016-06-21 2017-12-28 Therapure Biopharma Inc. Hemoglobin-targeted drug delivery for the treatment of cancer
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CU20190106A7 (es) 2017-06-26 2020-11-30 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
JPWO2019124423A1 (ja) * 2017-12-19 2020-10-22 国立大学法人 岡山大学 がんの進行抑制、治療、予防及び／又は再発予防剤
CN111558032B (zh) * 2020-05-19 2023-08-22 中国科学院宁波材料技术与工程研究所 一种蛋白纳米药物及其制备方法与应用
CN114344263B (zh) * 2022-02-21 2023-08-01 杭州普略生物科技有限公司 一种用于靶向巨噬细胞增强肿瘤治疗效果的纳米蛋白胶束及其制备方法和应用
KR102793996B1 (ko) 2022-03-31 2025-04-09 충남대학교산학협력단 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물
WO2025222059A1 (en) * 2024-04-17 2025-10-23 Prolong Pharmaceuticals Llc Method of treating cancer using pegylated bovine hemoglobin
CN119746044A (zh) * 2025-03-06 2025-04-04 润方（北京）生物医药研究院有限公司 血红蛋白氧载体在制备抗病毒药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
JP2006508939A (ja) * 2002-10-29 2006-03-16 エンジーン， インコーポレイテッド 癌処置のための組成物
EP2389068A4 (en) * 2009-01-23 2012-07-18 Cancer Rec Tech Ltd HEMGE OF THE HEDGEHOG SIGNAL PATH
DK3266463T3 (da) * 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
WO2011005886A1 (en) * 2009-07-07 2011-01-13 Normoxys, Inc. Method of reducing multi-drug resistance using inositol tripyrophosphate
US8808748B2 (en) * 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US20110319332A1 (en) * 2010-06-23 2011-12-29 Bing Lou Wong Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8048856B1 (en) * 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) * 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Also Published As

Publication number Publication date
CA2884521A1 (en) 2014-04-17
TW201414489A (zh) 2014-04-16
CN104717966A (zh) 2015-06-17
EP2906222A1 (en) 2015-08-19
PH12015500562A1 (en) 2015-05-04
SG10201607846PA (en) 2016-11-29
WO2014059199A1 (en) 2014-04-17
ZA201501949B (en) 2016-01-27
UY35082A (es) 2014-07-31
CA2884521C (en) 2018-05-01
AU2013329121A1 (en) 2015-04-09
PH12015500562B1 (en) 2015-05-04
IL237763A (en) 2017-07-31
AR093023A1 (es) 2015-05-13
KR20150065881A (ko) 2015-06-15
MA37994A2 (fr) 2016-06-30
CL2015000897A1 (es) 2015-08-21
US9056098B2 (en) 2015-06-16
HK1206281A1 (en) 2016-01-08
BR112015007475A2 (pt) 2017-08-08
EA201500301A1 (ru) 2015-08-31
AU2013329121B2 (en) 2017-05-25
AP2015008315A0 (en) 2015-03-31
US20140106004A1 (en) 2014-04-17
MX367562B (es) 2019-08-27
US20140303085A1 (en) 2014-10-09
CN104717966B (zh) 2018-08-24
MX2015004512A (es) 2015-12-01
EP2906222A4 (en) 2016-06-22
SG11201502133SA (en) 2015-04-29
JP2015534946A (ja) 2015-12-07
WO2014059199A8 (en) 2014-05-30
SG10201608747RA (en) 2016-12-29

Similar Documents

Publication Publication Date Title
JP2015534946A (ja) がんの標的治療およびがんの再発予防のためのヘモグロビンベース系酸素運搬体含有医薬組成物
Kinoh et al. Translational nanomedicine boosts anti-PD1 therapy to eradicate orthotopic PTEN-negative glioblastoma
CA3099434C (en) Targeting m2-like tumor-associated macrophages by using melittin-based pro-apoptotic peptide
CN111787945A (zh) 作为癌症免疫治疗的检查点阻断剂的工程化纳米囊泡
JP7042496B2 (ja) Ｒｕｎｘ阻害剤
WO2016000616A1 (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
JP6100252B2 (ja) 異なる治療用途のための熱安定性酸素キャリアを含有する医薬組成物
Luo et al. Genetically engineered biomimetic nanoparticles for synergistic activation of glioma-associated macrophages against glioblastoma
JP2018035112A (ja) 抗癌剤の抗腫瘍効果の増強剤、癌治療剤、及び癌治療用医薬組成物。
US12059429B2 (en) Hornerin: a novel non-VEGF mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells
US20130202625A1 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
WO2025242237A1 (zh) 工程化细胞膜纳米囊泡及其制备方法和应用
TWI882136B (zh) 類視色素與癌症治療藥之併用療法有效之癌症患者之選擇方法及類視色素與癌症治療藥之併用醫藥
WO2020227682A1 (en) Treating cancer
KR102119197B1 (ko) 세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물
Hung et al. Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer
HK1206281B (en) Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
Li et al. An albumin-prodrug injectable formulation for synergistic cancer immunotherapy
AU2019266231B2 (en) Selection of patients for combination therapy
US20180230466A1 (en) Methods for treating tumors
Rahmy Overcoming Resistance to Immune Checkpoint Blockade Therapy
JP2025541984A (ja) 抗腫瘍免疫応答を刺激するための薬物結合体化合物
Miyauchi The Role of Neuropilin 1 in Glioma Associated Microglia and Macrophages
WO2020158863A1 (ja) アントラサイクリン系化合物を含むミセル剤と免疫賦活剤との組み合わせ医薬
BR112017019862B1 (pt) Uso de uma proteína h-nox trimérica na preparação de uma composição para o tratamento de câncer e kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161011

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20161021

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20161110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170315

R150 Certificate of patent or registration of utility model

Ref document number: 6113850

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees